GKOS:NYE-Glaukos Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 88.3

Change

-1.96 (-2.17)%

Market Cap

USD 5.15B

Volume

0.67M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-1.09 (-0.83%)

USD 220.05B
MDT Medtronic PLC

-0.80 (-0.97%)

USD 106.32B
ZBH Zimmer Biomet Holdings Inc

-1.75 (-1.79%)

USD 22.25B
STE STERIS plc

-3.45 (-1.55%)

USD 22.15B
SNN Smith & Nephew SNATS Inc

-0.23 (-0.89%)

USD 11.31B
PEN Penumbra Inc

-6.71 (-2.42%)

USD 10.73B
GMED Globus Medical

-1.62 (-2.28%)

USD 9.77B
BIO Bio-Rad Laboratories Inc

-1.30 (-0.55%)

USD 6.94B
BIO-B Bio-Rad Laboratories Inc

+9.12 (+4.05%)

USD 6.39B
INSP Inspire Medical Systems Inc

-5.51 (-3.67%)

USD 4.39B

ETFs Containing GKOS

WELL:PA HAN-GINS Indxx Healthcare.. 3.20 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.20 % 0.00 %

N/A

N/A
VIOG Vanguard S&P Small-Cap 60.. 1.19 % 0.20 %

-2.16 (0.00%)

USD 0.74B
MWON:XETRA Amundi S&P SmallCap 600 E.. 1.01 % 0.00 %

N/A

N/A
USASUS:SW Amundi S&P SmallCap 600 E.. 0.84 % 0.00 %

N/A

USD 0.41B
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.77 (0.00%)

USD 0.16B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

-1.87 (0.00%)

N/A
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

-1.62 (0.00%)

N/A
ZSML:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

-0.84 (0.00%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 0.00 % 0.00 %

-0.55 (0.00%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.11% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.11% 14% F 4% F
Trailing 12 Months  
Capital Gain -10.76% 54% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.76% 54% F 23% F
Trailing 5 Years  
Capital Gain 159.63% 96% N/A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 159.63% 96% N/A 83% B
Average Annual (5 Year Horizon)  
Capital Gain 31.54% 91% A- 90% A-
Dividend Return 31.54% 91% A- 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.64% 29% F 17% F
Risk Adjusted Return 62.27% 97% N/A 75% C
Market Capitalization 5.15B 71% C- 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector